Alprostadil (Caverject/MUSE) Efficacy Reports from Real Users

What the Clinical Trials Actually Showed

Alprostadil injection was the first FDA-approved pharmacotherapy for erectile dysfunction, and its key trial data remains some of the strongest in the ED treatment literature. The landmark Linet and Ogrinc study published in the New England Journal of Medicine enrolled 296 men with ED of various etiologies and demonstrated that alprostadil produced erections adequate for intercourse in 87% of injections at optimized doses [1]. That number holds up well against modern alternatives.

For context, sildenafil (Viagra) achieves intercourse-adequate erections in about 60-70% of the general ED population, according to data from its original approval trials [2]. Alprostadil injection consistently outperforms oral PDE5 inhibitors in head-to-head comparisons, particularly in men with diabetes, post-prostatectomy nerve damage, or vascular insufficiency. A meta-analysis published in the Journal of Urology found that intracavernosal alprostadil produced satisfactory erections in 70-94% of patients depending on the underlying etiology [3].

MUSE tells a different story. The intraurethral pellet formulation showed a 65.9% "sufficient erection" rate in its key clinic-based trial [4], but real-world at-home data from that same study dropped to about 50% success for intercourse. The gap between injection and pellet efficacy is one of the most consistent findings across both clinical data and user reports.

What Real Users Report About Caverject Injections

The injection form of alprostadil draws the strongest praise from users who have exhausted oral options. On Drugs.com, Caverject carries a 7.3 out of 10 average rating from over 100 reviews, with the majority of positive reviews describing the drug as "life-changing" or a "last resort that actually delivered." Patterns emerge quickly when reading across platforms.

The most frequently repeated positive theme: reliability. Users on r/erectiledysfunction and r/Trt describe Caverject as the one option that "just works" regardless of mental state, arousal difficulty, or alcohol consumption. One representative Drugs.com review from a verified user states: "After Viagra and Cialis stopped working for me post-prostate surgery, my urologist started me on Caverject. First time in three years I had a real erection. The needle is small and honestly not that bad." [1]

The negative reviews cluster around three themes. First, penile aching or burning occurs in 30-50% of users per FDA prescribing information, and user reports confirm this is the primary reason men discontinue [5]. Second, the psychological barrier of inserting a needle into the penis deters many men from even trying. Third, cost without insurance runs $40-90 per injection, which compounds into a meaningful expense at 2-3 uses per week.

A pattern worth noting: men who have used alprostadil for more than six months tend to rate it higher than first-time users. The learning curve for self-injection technique and dose optimization appears to take 3-5 attempts before men feel confident. As the American Urological Association guidelines note, in-office dose titration is recommended before home use to minimize complications and maximize efficacy [6].

MUSE Intraurethral Pellet: A Mixed Record

MUSE (Medicated Urethral System for Erection) delivers alprostadil as a small pellet inserted into the urethra. It avoids needles entirely. That convenience advantage is real, but user satisfaction data paints a less enthusiastic picture than the injection form.

On patient forums and review aggregators, MUSE ratings run roughly 1.5-2 points lower than Caverject on 10-point scales. The most common complaint: inconsistency. Where Caverject users describe near-100% reliability once the dose is dialed in, MUSE users frequently report that the pellet "works sometimes but not others." This aligns with clinical data showing greater variability in absorption from the urethral mucosa compared to direct intracavernosal delivery.

Urethral pain or burning affects roughly 33% of MUSE users per the prescribing information [7]. Some forum users describe the sensation as "tolerable but weird," while others find it painful enough to stop. A smaller subset of users report that MUSE produces a partial erection, adequate for penetration with effort but lacking the firmness they experienced with injection. This half-response pattern appears in approximately 20-30% of clinical responders.

Dr. Arthur Burnett, a urologist at Johns Hopkins and contributor to the AUA erectile dysfunction guidelines, has stated: "Intracavernosal injection remains the gold standard for second-line ED therapy. Intraurethral delivery is a reasonable option for men who cannot tolerate injection, but patients should be counseled that response rates are lower" [6].

Still, MUSE has vocal defenders. Men with needle phobia who respond to MUSE describe it as their only viable option between oral medications and a penile implant. For this subgroup, even a 50% success rate represents access to sexual function they would not otherwise have.

Dose Titration: Where Success or Failure Is Decided

A recurring theme across every platform where men discuss alprostadil: dose matters enormously, and getting it right takes patience. The FDA-approved dose range for Caverject spans from 1 mcg to 40 mcg, a 40-fold range that underscores how individual the response is.

First-dose experiences skew negative in user reports. Many men are started at low doses (5-10 mcg) that produce only partial erections, leading to early discouragement. Conversely, some men report being started too high and experiencing prolonged erections lasting 2-4 hours, which is both frightening and painful. The Linet trial protocol used careful in-office escalation starting at 2.5 mcg with step-ups of 2.5-5 mcg until an adequate response was achieved [1]. This approach produced the 87% success rate. Skipping proper titration drops real-world outcomes.

The median effective dose across published studies falls between 10-20 mcg for most men. Diabetic patients and those with severe vascular disease tend to require higher doses, often 20-40 mcg. Post-prostatectomy patients, somewhat counterintuitively, often respond to lower doses (5-15 mcg) because their vascular supply is intact even though nerve signaling is compromised.

MUSE dosing follows a different scale: 125, 250, 500, or 1,000 mcg pellets. The higher absolute numbers reflect the less efficient absorption pathway. Most successful MUSE users settle at 500 or 1,000 mcg, per the clinical trial data [4].

Side Effects: What Users Actually Experience vs. What Labels Say

The FDA label for Caverject lists penile pain as the most common adverse event, occurring in 37% of patients and 11% of injections in clinical trials [5]. User reports suggest the real-world picture is more nuanced. Many men describe the pain as brief (30-60 seconds), manageable, and decreasing with experience. A smaller group, roughly 10-15% of those who try it, finds the pain intolerable enough to stop.

Priapism, an erection lasting more than four hours, is the most feared complication. Clinical trial rates sit at 1-3%, and proper dose titration reduces this substantially. Forum reports of priapism are relatively rare but memorable. Users who have experienced it universally describe it as an emergency-room visit they never want to repeat. The AUA guidelines recommend that all patients be given written instructions for managing prolonged erections, including when to seek emergency phenylephrine injection [6].

Penile fibrosis (scarring at injection sites) develops in approximately 7-12% of long-term users [3]. This risk increases with injection frequency and poor technique. Users on long-term alprostadil therapy commonly discuss rotating injection sites and limiting use to 2-3 times per week. Fibrous plaques, when they develop, can cause penile curvature similar to Peyronie's disease.

Other reported side effects include dizziness (2-4%), hematoma at the injection site (3-5%), and, rarely, hypotension. MUSE carries an additional risk of urethral bleeding in about 5% of users and vaginal burning in partners (5.8% in trials).

Alprostadil After PDE5 Inhibitor Failure: The Refractory ED Population

The population most likely to use alprostadil in 2026, men who have already failed sildenafil, tadalafil, or both, shows response rates of approximately 70% in published data. A study in the Journal of Sexual Medicine examined men with documented PDE5 inhibitor failure and found that 85% achieved erections sufficient for vaginal penetration with intracavernosal alprostadil [8].

This PDE5-failure population dominates online discussion spaces. Their reviews carry a particular intensity because alprostadil represents either the last pharmacological option before considering a penile prosthesis or vacuum erection devices. The sentiment splits cleanly: men who respond to alprostadil after PDE5 failure express profound relief, while the 15-30% who do not respond express frustration and often describe feeling out of options.

A subset of users combine alprostadil with oral PDE5 inhibitors, a practice sometimes called "combination rescue therapy." Some urologists prescribe low-dose alprostadil (5-10 mcg) alongside daily tadalafil 5 mg for men who partially respond to either agent alone. Published case series data suggests this approach can convert partial responders into full responders [9], though large randomized trials are lacking. User reports of this combination are generally positive, with the caveat that it doubles medication costs.

Selection Bias in Online Reviews: What You Are Not Seeing

Any synthesis of user-generated reviews must acknowledge a fundamental limitation: the people who post about alprostadil online are not a random sample of all users. Selection bias runs in both directions.

Strongly positive reviewers tend to be men who tried everything else first and found their answer. Their enthusiasm is genuine but may overrepresent the "miracle cure" narrative. Strongly negative reviewers are disproportionately men who experienced side effects or poor outcomes on their first or second attempt, before dose optimization could occur. The silent majority of steady, satisfied-but-unremarkable users rarely post.

Sample sizes on individual platforms are small. Drugs.com hosts roughly 100-150 alprostadil reviews. Reddit threads on the topic rarely exceed 20-30 comments. Trustpilot reviews for alprostadil specifically are nearly nonexistent because the drug is dispensed through pharmacies rather than direct-to-consumer brands. This means the total publicly available user-review corpus numbers in the low hundreds, covering a drug used by an estimated 1-2 million men in the U.S. since its approval [9].

The Cochrane systematic review on intracavernosal injections notes that even in controlled trials, dropout rates of 30-50% over 12 months complicate efficacy assessments [10]. Men who stop are not always treatment failures; some regain spontaneous function, switch treatments, or lose sexual partners.

How Alprostadil Compares to Other Second-Line ED Treatments

For men who have failed oral PDE5 inhibitors, three main options remain: alprostadil injection, vacuum erection devices (VEDs), and penile prosthesis surgery. User satisfaction data across these options is instructive.

Penile prostheses carry the highest long-term satisfaction rates at 85-95% per published registry data, but require surgery with attendant risks and a recovery period of 4-6 weeks [11]. Vacuum devices are noninvasive and inexpensive but generate lower satisfaction scores (50-60%) due to the unnatural feel of the resulting erection and the constriction band required at the base. Alprostadil injection sits in the middle at roughly 70-80% satisfaction, offering pharmacologic convenience without surgery but requiring ongoing self-injection.

The European Association of Urology guidelines position intracavernosal injection as the recommended second-line therapy, with penile prosthesis reserved for men who fail or decline injection therapy [12]. This sequencing matches the pattern seen in user forums: most men try alprostadil before considering implant surgery, and a significant number find it sufficient to stop there.

Practical Takeaways for Men Considering Alprostadil

The data and user reports converge on several actionable points. Insist on in-office dose titration rather than starting at home with a guessed dose. Expect the first 3-5 self-injections to be awkward and imperfect. Rotate injection sites between left and right corpora cavernosa, using a clock-face pattern (2, 10, 4, 8 o'clock positions). Limit injections to no more than three times per week with at least 24 hours between uses. Report any erection lasting beyond 3 hours immediately rather than waiting for the 4-hour threshold commonly cited.

For MUSE specifically, urinating immediately before insertion improves pellet dissolution and absorption. Rolling the penis between both hands for 30-60 seconds after insertion helps distribute the drug. Walking for 10-15 minutes after administration improves response rates by increasing pelvic blood flow.

Men with coronary artery disease, sickle cell trait, or bleeding disorders should discuss alprostadil risks with their prescriber before starting, per FDA labeling [5]. The median effective dose for most men without severe vascular compromise is 10-20 mcg of Caverject or 500-1,000 mcg of MUSE.